Phase II study of sorafenib in patients with relapsed or refractory lymphoma

• DOI: 10.1111/j.1365-2141.2012.09139.x
• Publication Date: 2012-05-10T10:21:26Z
• Authors: Anna Guidetti; Carmelo Carlo‐Stella; Silvia L. Locatelli; Walter Malorni; Marina Pierdominici; Cristiana Barbati; Roberta Mortarini; Lilli Devizzi; Paola Matteucci; Alfonso Marchianò; Rodolfo Lanocita; Lucia Farina; Anna Dodero; Corrado Tarella; Massimo Di Nicola; Paolo Corradini; Andrea Anichini; Alessandro M. Gianni
• Keywords: Refractory (planetary science); Clinical endpoint

The safety and activity of the multikinase inhibitor sorafenib were investigated in patients with relapsed or refractory lymphoproliferative disorders who received (400 mg) twice daily until disease progression appearance significant clinical toxicity. primary endpoint was overall response rate (ORR). Biomarkers analysed at baseline during treatment. Thirty (median age, 61 years; range, 18-74) a median 4 months therapy. Grade 3-4 toxicities included hand/foot skin reactions (20%), infections (12%), neutropenia (20%) thrombocytopenia (14%). Two achieved complete remission (CR), two partial (PR) for an ORR 13%. Stable (SD) progressive (PD) observed 15 (50%) 11 (37%), respectively. survival (OS) all 16 months. For CR, PR SD, time to OS 5 24 months, Compared PD, responsive had significantly higher levels extracellular signal-regulated kinase phosphorylation autophagy presented reduction these parameters after 1 month Sorafenib well tolerated that warrants development combination regimens.